AT-101 is under clinical development by Ascenta Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AT-101 overview

AT-101 is under development for the treatment of chronic lymphocytic leukemia (CLL), relapsed/refractory multiple myeloma and squamous cell carcinoma of the larynx and hypopharynx. The drug candidate is administered through oral route. It acts by targeting pan-Bcl-2 protein. It was under development for the treatment of small cell lung cancer, men with chemotherapy-naive metastatic hormone-refractory prostate cancer (HRPC), diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, adrenocortical carcinoma (adrenal cortex cancer), esophageal or gastroesophageal junction cancer, non-small cell lung cancer, recurrent head and neck cancer squamous cell cancer, glioblastoma multiforme and metastatic prostate cancer.

Ascenta Therapeutics overview

Ascenta Therapeutics (Ascenta) is a biopharmaceutical company that research, develops and manufactures drugs to treat cancer. Ascenta is headquartered in Malvern, Pennsylvania, the US.

For a complete picture of AT-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.